tizanidine has been researched along with Disease Models, Animal in 10 studies
tizanidine: RN given refers to parent cpd; structure
tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 7.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "Intrathecally administered alpha2-adrenergic receptor subtype-specific antagonists were used to determine which alpha2-adrenergic receptor subtype mediates the analgesic effect of intrathecally administered tizanidine in a chronic constriction injury (CCI) rat model of neuropathic pain." | 7.72 | Alpha2-adrenergic receptor subtype specificity of intrathecally administered tizanidine used for analgesia for neuropathic pain. ( Dills, CV; Leiphart, JW; Levy, RM, 2004) |
| " Although rigidity was reduced by efaroxan (an imidazoline I(1) receptor and alpha(2)-adrenoceptor antagonist) and idazoxan (an imidazoline I(1) and I(2) receptor and alpha(2)-adrenoceptor antagonist), SKF86466 and yohimbine, both of which are alpha(2)-adrenoceptor antagonists with no affinity for imidazoline receptors, also suppressed rigidity, suggesting that activation rather than blockade of imidazoline I(1) receptors contributes to reduction of reserpine-induced muscle rigidity." | 3.74 | Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. ( Hashimoto, M; Ono, H; Tanabe, M, 2008) |
| "Intrathecally administered alpha2-adrenergic receptor subtype-specific antagonists were used to determine which alpha2-adrenergic receptor subtype mediates the analgesic effect of intrathecally administered tizanidine in a chronic constriction injury (CCI) rat model of neuropathic pain." | 3.72 | Alpha2-adrenergic receptor subtype specificity of intrathecally administered tizanidine used for analgesia for neuropathic pain. ( Dills, CV; Leiphart, JW; Levy, RM, 2004) |
| " The first group was used as control group (Control) (n = 20), in the second group subarachnoid hemorrhage was performed (SAH) (n = 20), in the third group Tizanidine was administered in addition to SAH (SAH + Tizanidine administration) (n = 20)." | 3.70 | The effect of tizanidine on chronic vasospasm in rats. ( Berkman, MK; Berkman, MZ; Erbengi, T; Iplikçioğlu, AC; San, T; Sav, A, 2000) |
| "Tizanidine was given systemically to rats with experimental postoperative pain." | 1.31 | Systemic tizanidine hydrochloride (Zanaflex) partially decreases experimental postoperative pain in rats. ( Azevedo, MI; Denson, DD; Hord, AH, 2001) |
| "Tizanidine was effective in reducing sensitivity to heat, as measured by paw withdrawal latency, and did not cause sedation at smaller doses." | 1.31 | Systemic tizanidine hydrochloride (Zanaflex) relieves thermal hyperalgesia in rats with an experimental mononeuropathy. ( Azevedo, MI; Chalfoun, AG; Denson, DD; Hord, AH, 2001) |
| "Tizanidine was administered orally at 0." | 1.30 | Effects of tizanidine administration on precipitated opioid withdrawal signs in rats. ( Pinelli, A; Spezia, R; Trivulzio, S, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Beltrán-Villalobos, KL | 1 |
| Ramírez-Marín, PM | 1 |
| Cruz, CA | 1 |
| Déciga-Campos, M | 1 |
| Tanabe, M | 1 |
| Hashimoto, M | 1 |
| Ono, H | 1 |
| Fuchigami, T | 1 |
| Kakinohana, O | 1 |
| Hefferan, MP | 1 |
| Lukacova, N | 1 |
| Marsala, S | 1 |
| Platoshyn, O | 1 |
| Sugahara, K | 1 |
| Yaksh, TL | 1 |
| Marsala, M | 1 |
| Leiphart, JW | 1 |
| Dills, CV | 1 |
| Levy, RM | 1 |
| Pinelli, A | 1 |
| Trivulzio, S | 1 |
| Spezia, R | 1 |
| Berkman, MZ | 1 |
| Iplikçioğlu, AC | 1 |
| Berkman, MK | 1 |
| Erbengi, T | 1 |
| San, T | 1 |
| Sav, A | 1 |
| Hord, AH | 2 |
| Denson, DD | 2 |
| Azevedo, MI | 2 |
| Chalfoun, AG | 1 |
10 other studies available for tizanidine and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Coadministration of tramadol and tizanidine in an experimental acute pain model in rat.
Topics: Acute Pain; Analgesics; Animals; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug | 2014 |
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines | 2008 |
Potent suppression of stretch reflex activity after systemic or spinal delivery of tizanidine in rats with spinal ischemia-induced chronic spastic paraplegia.
Topics: Animals; Chronic Disease; Clonidine; Disease Models, Animal; Male; Muscle Relaxants, Central; Neural | 2011 |
Alpha2-adrenergic receptor subtype specificity of intrathecally administered tizanidine used for analgesia for neuropathic pain.
Topics: Adrenergic alpha-Agonists; Analgesia; Animals; Clonidine; Disease Models, Animal; Injections, Spinal | 2004 |
Effects of tizanidine administration on precipitated opioid withdrawal signs in rats.
Topics: Adrenergic alpha-Agonists; Analgesics; Analysis of Variance; Animals; Behavioral Symptoms; Body Temp | 1998 |
The effect of tizanidine on chronic vasospasm in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Chronic Disease; Clonidine; Disease Models, Animal; F | 2000 |
Systemic tizanidine hydrochloride (Zanaflex) partially decreases experimental postoperative pain in rats.
Topics: Adrenergic alpha-Agonists; Analgesics; Animals; Clonidine; Disease Models, Animal; Male; Pain, Posto | 2001 |
Systemic tizanidine hydrochloride (Zanaflex) relieves thermal hyperalgesia in rats with an experimental mononeuropathy.
Topics: Adrenergic alpha-Agonists; Animals; Clonidine; Disease Models, Animal; Hot Temperature; Hyperalgesia | 2001 |